Cingulate (CING) Cash & Equivalents (2021 - 2026)
Cingulate's (CING) quarterly Cash & Equivalents came in at $11.0 million in Q4 2025, down 10.3% YoY from $12.2 million in Q4 2024, and up 79.56% on a QoQ basis from $6.1 million in Q3 2025.
Cingulate (CING) Cash & Equivalents (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Cash & Equivalents data on file, last reported at $11.0 million in Q4 2025.
- Quarterly Cash & Equivalents fell 10.3% year-over-year to $11.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.0 million (down 10.3% YoY) and the FY2025 annual result came in at $11.0 million, down 10.3% from the prior year.
- Cash & Equivalents improved to $11.0 million in Q4 2025, from $6.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $16.5 million in Q4 2021 to a low of $52416.0 in Q4 2023.
- A 5-year average of $6.7 million and a median of $7.1 million in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 99.02% — and 2024, when it soared 23196.93%.
- Tracing CING's Cash & Equivalents over 5 years: stood at $16.5 million in 2021, then slumped by 67.52% to $5.4 million in 2022, then tumbled by 99.02% to $52416.0 in 2023, then soared by 23196.93% to $12.2 million in 2024, then decreased by 10.3% to $11.0 million in 2025.
- The last three Cash & Equivalents figures came in at $11.0 million (Q4 2025), $6.1 million (Q3 2025), and $9.5 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 28.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.40 Mn |
| Dec 31, 2025 | 10.95 Mn |
| Sep 30, 2025 | 6.10 Mn |
| Mar 31, 2025 | 9.50 Mn |
| Dec 31, 2024 | 12.21 Mn |
| Sep 30, 2024 | 10.04 Mn |
| Jun 30, 2024 | 380,928.00 |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 52,416.00 |
| Sep 30, 2023 | 1.99 Mn |
| Jun 30, 2023 | 349,831.00 |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 5.36 Mn |
| Sep 30, 2022 | 9.80 Mn |
| Jun 30, 2022 | 8.20 Mn |
| Mar 31, 2022 | 12.61 Mn |
| Dec 31, 2021 | 16.49 Mn |